nsc 659853

2-Methoxyestradiol (2-ME2) is an orally bioavailable estradiol metabolite with potential antineoplastic activity. 2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis. This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis.

2-Methoxyestradiol (Standard) is a reference standard for research and analysis in studies involving 2-Methoxyestradiol. 2-Methoxyestradiol (2-ME2) is an orally bioavailable estradiol metabolite with potential antineoplastic activity. 2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis. This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis.

2-Methoxyestradiol-13C6 is a 13C-labeled version of 2-Methoxyestradiol. 2-Methoxyestradiol (2-ME2) is an orally active endogenous metabolite of 17β-estradiol (E2) that functions as an apoptosis inducer and an angiogenesis inhibitor with significant antitumor activity. It also disrupts the stability of microtubules. Furthermore, 2-Methoxyestradiol is a potent inhibitor of superoxide dismutase (SOD) and a promoter of reactive oxygen species generation, inducing autophagy in transformed cell line HEK293, and cancer cell lines U87 and HeLa.

2-Methoxyestradiol-d5 is the deuterated form of 2-Hydroxyestradiol. Derived from 2-Methoxyestradiol (2-ME2), an orally active metabolite of 17β-estradiol (E2), it serves as an inducer of apoptosis and an inhibitor of angiogenesis, demonstrating potent antitumor activity. Additionally, 2-Methoxyestradiol disrupts the stability of microtubules and acts as an effective superoxide dismutase.